• Je něco špatně v tomto záznamu ?

Uncovering mechanisms of thiazolidinediones on osteogenesis and adipogenesis using spatial fluxomics

K. Brejchova, M. Rahm, A. Benova, V. Domanska, P. Reyes-Gutierez, M. Dzubanova, R. Trubacova, M. Vondrackova, T. Cajka, M. Tencerova, M. Vrabel, O. Kuda

. 2025 ; 166 (-) : 156157. [pub] 20250211

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009296

OBJECTIVE: Insulin-sensitizing drugs, despite their broad use against type 2 diabetes, can adversely affect bone health, and the mechanisms underlying these side effects remain largely unclear. Here, we investigated the different metabolic effects of a series of thiazolidinediones, including rosiglitazone, pioglitazone, and the second-generation compound MSDC-0602K, on human mesenchymal stem cells (MSCs). METHODS: We developed 13C subcellular metabolomic tracer analysis measuring separate mitochondrial and cytosolic metabolite pools, lipidomic network-based isotopologue models, and bioorthogonal click chemistry, to demonstrate that MSDC-0602K differentially affected bone marrow-derived MSCs (BM-MSCs) and adipose tissue-derived MSCs (AT-MSCs). In BM-MSCs, MSDC-0602K promoted osteoblastic differentiation and suppressed adipogenesis. This effect was clearly distinct from that of the earlier drugs and that on AT-MSCs. RESULTS: Fluxomic data reveal unexpected differences between this drug's effect on MSCs and provide mechanistic insight into the pharmacologic inhibition of mitochondrial pyruvate carrier 1 (MPC). Our study demonstrates that MSDC-0602K retains the capacity to inhibit MPC, akin to rosiglitazone but unlike pioglitazone, enabling the utilization of alternative metabolic pathways. Notably, MSDC-0602K exhibits a limited lipogenic potential compared to both rosiglitazone and pioglitazone, each of which employs a distinct lipogenic strategy. CONCLUSIONS: These findings indicate that the new-generation drugs do not compromise bone structure, offering a safer alternative for treating insulin resistance. Moreover, these results highlight the ability of cell compartment-specific metabolite labeling by click reactions and tracer metabolomics analysis of complex lipids to discover molecular mechanisms within the intersection of carbohydrate and lipid metabolism.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009296
003      
CZ-PrNML
005      
20250429135054.0
007      
ta
008      
250415e20250211xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.metabol.2025.156157 $2 doi
035    __
$a (PubMed)39947516
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Brejchova, Kristyna $u Laboratory of Metabolism of Bioactive Lipids, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
245    10
$a Uncovering mechanisms of thiazolidinediones on osteogenesis and adipogenesis using spatial fluxomics / $c K. Brejchova, M. Rahm, A. Benova, V. Domanska, P. Reyes-Gutierez, M. Dzubanova, R. Trubacova, M. Vondrackova, T. Cajka, M. Tencerova, M. Vrabel, O. Kuda
520    9_
$a OBJECTIVE: Insulin-sensitizing drugs, despite their broad use against type 2 diabetes, can adversely affect bone health, and the mechanisms underlying these side effects remain largely unclear. Here, we investigated the different metabolic effects of a series of thiazolidinediones, including rosiglitazone, pioglitazone, and the second-generation compound MSDC-0602K, on human mesenchymal stem cells (MSCs). METHODS: We developed 13C subcellular metabolomic tracer analysis measuring separate mitochondrial and cytosolic metabolite pools, lipidomic network-based isotopologue models, and bioorthogonal click chemistry, to demonstrate that MSDC-0602K differentially affected bone marrow-derived MSCs (BM-MSCs) and adipose tissue-derived MSCs (AT-MSCs). In BM-MSCs, MSDC-0602K promoted osteoblastic differentiation and suppressed adipogenesis. This effect was clearly distinct from that of the earlier drugs and that on AT-MSCs. RESULTS: Fluxomic data reveal unexpected differences between this drug's effect on MSCs and provide mechanistic insight into the pharmacologic inhibition of mitochondrial pyruvate carrier 1 (MPC). Our study demonstrates that MSDC-0602K retains the capacity to inhibit MPC, akin to rosiglitazone but unlike pioglitazone, enabling the utilization of alternative metabolic pathways. Notably, MSDC-0602K exhibits a limited lipogenic potential compared to both rosiglitazone and pioglitazone, each of which employs a distinct lipogenic strategy. CONCLUSIONS: These findings indicate that the new-generation drugs do not compromise bone structure, offering a safer alternative for treating insulin resistance. Moreover, these results highlight the ability of cell compartment-specific metabolite labeling by click reactions and tracer metabolomics analysis of complex lipids to discover molecular mechanisms within the intersection of carbohydrate and lipid metabolism.
650    _2
$a lidé $7 D006801
650    12
$a thiazolidindiony $x farmakologie $7 D045162
650    12
$a adipogeneze $x účinky léků $7 D050156
650    12
$a osteogeneze $x účinky léků $7 D010012
650    12
$a mezenchymální kmenové buňky $x účinky léků $x metabolismus $7 D059630
650    _2
$a rosiglitazon $x farmakologie $7 D000077154
650    _2
$a kultivované buňky $7 D002478
650    _2
$a hypoglykemika $x farmakologie $7 D007004
650    _2
$a pioglitazon $x farmakologie $7 D000077205
650    _2
$a buněčná diferenciace $x účinky léků $7 D002454
650    _2
$a metabolomika $7 D055432
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rahm, Michal $u Chemistry of Bioconjugates, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague, Czechia
700    1_
$a Benova, Andrea $u Laboratory of Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
700    1_
$a Domanska, Veronika $u Laboratory of Metabolism of Bioactive Lipids, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
700    1_
$a Reyes-Gutierez, Paul $u Chemistry of Bioconjugates, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague, Czechia
700    1_
$a Dzubanova, Martina $u Laboratory of Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia; Faculty of Science, Charles University, Albertov 6, 128 00 Prague, Czech Republic
700    1_
$a Trubacova, Radka $u Laboratory of Metabolism of Bioactive Lipids, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
700    1_
$a Vondrackova, Michaela $u Laboratory of Metabolism of Bioactive Lipids, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
700    1_
$a Cajka, Tomas $u Laboratory of Translational Metabolism, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
700    1_
$a Tencerova, Michaela $u Laboratory of Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
700    1_
$a Vrabel, Milan $u Chemistry of Bioconjugates, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague, Czechia
700    1_
$a Kuda, Ondrej $u Laboratory of Metabolism of Bioactive Lipids, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia. Electronic address: ondrej.kuda@fgu.cas.cz
773    0_
$w MED00010225 $t Metabolism, clinical and experimental $x 1532-8600 $g Roč. 166 (20250211), s. 156157
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39947516 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135049 $b ABA008
999    __
$a ok $b bmc $g 2310961 $s 1246377
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 166 $c - $d 156157 $e 20250211 $i 1532-8600 $m Metabolism, clinical and experimental $n Metabolism $x MED00010225
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...